周选股参赛一得

为了参加周选股赛，注意到：2014 FDA Drug Approval Decision Calendar
从中选了短期有活力的三个：AUXL, GSK, ANAC。结果ANAC表现异常好，一不留神整个第一。再挖挖，里面还有宝。

 

 

 

 

December 2013: Drug approval decisions:

 

 

Gilead Sciences 

Sofo*****uvir for hepatitis C
 

Dec. 6
 

 

Auxilium Pharmaceuticals

Dec. 6
 

 

GlaxoSmithKline 

Anoro Ellipta for COPD
 

Dec. 18
 

 

Amarin 

Vascepa for mixed dyslipidemia
 

Dec. 20
 

 

 

 

Bristol-Myers Squibb 

Metreleptin for lipodystrophy
 

Dec. 11
 

 

Bristol-Myers Squibb
 

Dapagliflozin for Type 2 diabetes
 

Dec. 12
 

 

 

 

Biogen Idec 

Alprolix for hemophilia B
 

Jan. 3
 

 

Bristol-Myers Squibb
 

Dapagliflozin for Type 2 diabetes
 

Jan. 14
 

 

Pozen 

PA32540 & PA8140 for heart disease
 

Jan. 24
 

 

Vanda Pharmaceuticals 

Hetlioz for non-24 sleep disorder
 

Jan. 31
 

 

 

 

Chelsea Therapeutics

Northera for orthostatic hypotension
 

Jan. 14
 

 

Alimera Sciences 

Iluvien for diabetic macular edema
 

Jan. 27
 

 

 

 

Chelsea Therapeutics
 

Northera for orthostatic hypotension
 

Feb. 14
 

 

United Therapeutics 

Oral Remodulin for pulmonary arterial hypertension
 

Feb. 14
 

 

Bristol-Myers Squibb
 

Metreleptin for lipodystrophy
 

Feb. 27
 

 

Biomarin 

Vimizim for morquio syndrome
 

Feb. 28
 

 

Pharmacyclics 

Imbruvica for chronic lymphocytic leukemia
 

Feb. 28
 

 

 

 

Celgene 

Apremilast for psoriatic arthritis
 

March 21
 

 

 

 

MannKind 

Afrezza for Type 1 and 2 diabetes
 

April 15
 

 

GlaxoSmithKline 

Abiglutide for diabetes
 

April 15
 

 

Santarus 

Ruconest for hereditary angioedema
 

April 16
 

 

Click ahead for more FDA drug approval decision dates
 

 

 

(GILD_)
(AUXL_)Xiaflex for Peyronie's disease
(GSK_) and Theravance  (THRX_)
(AMRN_)
FDA advisory panels:
(BMY_)
January 2014: Drug approval decisions
(BIIB_)
(POZN_)
(VNDA_)
FDA advisory panels:
(CHTP_) 
(ALIM_) and pSivida  (PSDV_)
February 2014: Drug approval decisions
(UTHR_)
(BMRN_)
(PCYC_) and Johnson & Johnson  (JNJ_)
March 2014: Drug approval decisions
(CELG_)
April 2014: Drug approval decisions
(MNKD_)
(GSK)
(SNTS_)

 

AstraZeneca (AZN_)
(DRTX_)
June 2014: Drug approval decisions
(OMER_)
(LLY_)
(BDSI_)
(KERX_)
(CBST_)
July 2014: Drug approval decisions
(ANAC_)
September 2014: Drug approval decisions
(NKTR_)
October 2014: Drug approval decisions
(NPSP_)

Epanova for hypercholesterolemia
 

May 5
 

 

Gilead Sciences
 

Idelalisib for indolent non-Hodgkin's lymphoma
 

May 11 (pending FDA acceptance of priority review)
 

 

Biogen Idec
 

Plegridy for multiple sclerosis
 

May 21
 

 

Durata Therapeutics

Dalbavancin for skin infections
 

May 26
 

 

 

 

Omeros 

OMS302 for ocular inflammation
 

June 1
 

 

Eli Lilly 

Ramucirumab for gastric cancer
 

June 3
 

 

BioDelivery Sciences 

Bunavail for opioid addiction
 

June 7
 

 

Keryx Pharmaceuticals 

Zerenex for hyperphosphatemia (kidney dialysis)
 

June 7
 

 

Biogen Idec
 

Eloctate for hemophilia A
 

June 12
 

 

Cubist Pharma 

Tedizolid for skin infections
 

June 22 (pending FDA acceptance of priority review)
 

 

 

 

Anacor Pharma 

Tavaborole for toe fungus
 

July 29
 

 

 

 

AstraZeneca and Nektar Therapeutics 

Naloxegol for opioid-induced constipation
 

Sept. 16
 

 

 

 

NPS Pharmaceuticals 

Natpara for hypoparathyroidism
 

Oct. 24

所有跟帖： 

• 恭喜恭喜! 谢谢分享! -zyj1- ♂ (0 bytes) () 12/06/2013 postreply 17:15:52